Nav: Home

Experts tackle major cardiovascular issues in treating patients with HIV

March 04, 2019

Philadelphia, March 4, 2019 - Since the advent of effective antiretroviral therapy (ART), human immunodeficiency virus (HIV) infection has become more like a chronic illness. Now that patients are able to live longer and remain free of developing AIDS, they have begun to encounter new risks from age-related disorders common in the general population, including cardiovascular disease (CVD).

Who is best suited to treat these patients is not clear, since HIV specialists may not have the expertise to manage CVD, and cardiologists may lack adequate training in understanding HIV-related disease processes or treatments. To address these gaps in clinical care, the latest issue of the Canadian Journal of Cardiology presents up-to-date guidance for cardiologists and other clinicians who treat this growing and challenging patient population.

"Survivors of the AIDS epidemic face a variety of new threats to their health, including an increased risk of diabetes, chronic kidney disease, cancer, bone diseases, neurocognitive disorders, and CVD, due to the cumulative effects of exposure to HIV, prolonged immune suppression, chronic inflammation, and the adverse effects of ART," explains David D. Waters, MD, Division of Cardiology at Zuckerberg San Francisco General Hospital and the Department of Medicine of the University of California, San Francisco, CA, USA.

According to the Centers for Disease Control and Prevention, an estimated 1,122,900 adults and adolescents were living with HIV in the United States by the end of 2015. Of those, 162,500 (15 percent) had not received a diagnosis. Worldwide, an estimated 35 million people have HIV. Although deaths from AIDS-related illnesses have declined dramatically since the 1990s, deaths from CVD in people with HIV have more than doubled over the past two decades. Studies have shown a two-fold greater risk of myocardial infarction (MI) for persons with HIV even after adjusting for CVD risk factors. As more HIV patients age, cardiologists' services will be in even greater demand.

Cardiologist Priscilla Y. Hsue, MD, University of California, San Francisco (UCSF), Zuckerberg San Francisco Hospital, San Francisco, CA, USA, discusses mechanisms of cardiovascular disease in the setting of HIV infection. According to Dr. Hsue, the types of CVD occurring in HIV have shifted over the years from pericardial effusion and dilated cardiomyopathy to conditions such as atherosclerosis, arrhythmic complications, and heart failure. Factors that contribute to the pathogenesis of CVD in HIV include a preponderance of traditional risk factors (such as hypertension, lipid abnormalities, cigarette smoking, metabolic syndrome, diabetes, and chronic kidney disease), leaky gut and microbial translocation, T-cell activation and cytomegalovirus coinfection, chronic inflammation, platelet abnormalities, and side effects from antiretroviral therapy.

Even in the setting of effectively treated HIV infection, HIV-associated factors are strong contributors to CVD; for example, an association exists between chronic inflammation and CVD in both HIV and non-HIV patients. Dr. Hsue discusses evidence regarding the effectiveness of anti-inflammatory medications in reducing CVD events. She also makes the important point that persons living with HIV represent a unique model of chronic inflammation and thus, "findings gleaned from studies in HIV patients can help to identify anti-atherosclerotic targets that may benefit broader populations."

Dr. Hsue believes that the cellular mechanisms that underlie "ordinary" atherosclerosis may be amplified in HIV patients. "On a molecular level, monocytes/macrophages, platelet reactivity, and immune cell activation may be heightened in the setting of HIV and contribute to HIV-associated atherosclerosis." She also cites evidence that HIV-related atherosclerosis is structurally distinct from atherosclerosis in non-HIV individuals.

Caption: Mechanisms leading to atherosclerotic cardiovascular disease with human immunodeficiency virus (HIV) infection. This schematic figure illustrates the multiple and complex mechanisms leading to HIV-associated atherosclerosis in people living with HIV. While HIV infection is controlled by antiretroviral medication, HIV is not cured and thus persons living with HIV must take antiretroviral medications chronically.

Chronic inflammation and immune activation are also considered the primary drivers of HIV-associated coronary artery disease (CAD). Arjun Sinha, MD, MS, and Matthew Feinstein, MD, MS, examine the clinical features of CAD in HIV patients.

"Inflammation is now recognized as an important factor in cardiovascular disease, however, the reason for increased inflammation in patients who develop heart disease, especially in those living with HIV, remains unclear," notes Dr. Sinha, Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. "Despite treatment with antiretroviral therapy that eradicates the HIV virus from the blood, low levels of the virus remain active in the intestines leading to changes in the intestinal lining and bacteria. How these changes lead to increased inflammation and heart disease is an important area of research as it can have broader implications for the population at large."

Numerous studies have shown increased plaque buildup and heart attacks in people living with HIV. This is despite the fact that the vast majority are well treated with ART. During the initial years of ART, some HIV medications were thought to be the reason behind this increased risk because they would cause weight gain, high cholesterol, and triglycerides. While this was a valid concern, current ARTs do not have those side effects. However, the increased CVD risk remains. "We are learning that even after suppression of the virus in the blood with these newer agents, there is increased inflammation and changes in the immune system that put these individuals at a higher risk of heart attacks. The HIV virus still hides in certain parts of the body such as the intestines likely leading to these problematic changes," notes Dr. Feinstein, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

The authors also delve into differences in the presentation and outcomes of CAD and acute coronary syndrome between HIV-infected and non-infected patients, including lower age at presentation, more non-calcified plaque, increased risk of 30-day in-hospital mortality and recurrent MI, and higher risk of ST-segment elevation MIs, and the higher risks observed in women vs. men with HIV.

The authors emphasize the importance of early and continuous ART therapy in reducing CVD risk and find that many risk estimation tools developed from general populations underestimate CVD risk in HIV patients. "We also have to become better at predicting the risk of future cardiovascular events in people living with HIV so that we can identify who will benefit from starting therapies that are already available," comments Dr. Sinha.

This special issue also includes reviews on other cardiovascular concerns for patients with HIV, such as stroke, heart failure, pulmonary hypertension, and arrhythmias. Dr. Timothy Ryan and colleagues consider the role of vascular imaging in the risk assessment of people with HIV. Dr. Pierre Gigere provides an in-depth description of potential drug-drug interactions between ART and CV medications, which is especially important when treating patients who take multiple drugs and have several comorbidities. Dr. Bobby Yanagawa discusses cardiac surgery in HIV patients, including protective measures for the surgical staff.

"People with HIV have significantly higher risk for heart disease, including heart attack and heart failure, than people without HIV. This higher risk remains, even after accounting for demographic factors, common heart disease risk factors, and HIV medications. The majority of people with HIV in high income countries are now over 50 years old. This underscores the importance of understanding WHY people with HIV get heart disease and HOW we can curb the HIV-heart disease epidemic," says Dr. Feinstein.
-end-


Elsevier

Related Heart Disease Articles:

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.
Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.
Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.
New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.
Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.
Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.
Women once considered low risk for heart disease show evidence of previous heart attack scars
Women who complain about chest pain often are reassured by their doctors that there is no reason to worry because their angiograms show that the women don't have blockages in the major heart arteries, a primary cause of heart attacks in men.
Where you live could determine risk of heart attack, stroke or dying of heart disease
People living in parts of Ontario with better access to preventive health care had lower rates of cardiac events compared to residents of regions with less access, found a new study published in CMAJ (Canadian Medical Association Journal).
Older adults with heart disease can become more independent and heart healthy with physical activity
Improving physical function among older adults with heart disease helps heart health and even the oldest have a better quality of life and greater independence.
Dietary factors associated with substantial proportion of deaths from heart disease, stroke, and disease
Nearly half of all deaths due to heart disease, stroke, and type 2 diabetes in the US in 2012 were associated with suboptimal consumption of certain dietary factors, according to a study appearing in the March 7 issue of JAMA.
More Heart Disease News and Heart Disease Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Teaching For Better Humans 2.0
More than test scores or good grades–what do kids need for the future? This hour, TED speakers explore how to help children grow into better humans, both during and after this time of crisis. Guests include educators Richard Culatta and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 3: Shared Immunity
More than a million people have caught Covid-19, and tens of thousands have died. But thousands more have survived and recovered. A week or so ago (aka, what feels like ten years in corona time) producer Molly Webster learned that many of those survivors possess a kind of superpower: antibodies trained to fight the virus. Not only that, they might be able to pass this power on to the people who are sick with corona, and still in the fight. Today we have the story of an experimental treatment that's popping up all over the country: convalescent plasma transfusion, a century-old procedure that some say may become one of our best weapons against this devastating, new disease.   If you have recovered from Covid-19 and want to donate plasma, national and local donation registries are gearing up to collect blood.  To sign up with the American Red Cross, a national organization that works in local communities, head here.  To find out more about the The National COVID-19 Convalescent Plasma Project, which we spoke about in our episode, including information on clinical trials or plasma donation projects in your community, go here.  And if you are in the greater New York City area, and want to donate convalescent plasma, head over to the New York Blood Center to sign up. Or, register with specific NYC hospitals here.   If you are sick with Covid-19, and are interested in participating in a clinical trial, or are looking for a plasma donor match, check in with your local hospital, university, or blood center for more; you can also find more information on trials at The National COVID-19 Convalescent Plasma Project. And lastly, Tatiana Prowell's tweet that tipped us off is here. This episode was reported by Molly Webster and produced by Pat Walters. Special thanks to Drs. Evan Bloch and Tim Byun, as well as the Albert Einstein College of Medicine.  Support Radiolab today at Radiolab.org/donate.